Showing results (131-140 of 146) with videos related to

Sort By:
Pageof 15
Reports of Practical Oncology and Radiotherapy : Journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology|May 6, 2020
Impact of 68Ga-PSMA PET/CT in the treatment of prostate cancer: Initial experience in SpainFelipe Couñago, Claudio Martínez-Ballesteros, Carlos Artigas, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|October 13, 2022
Recommendations for radiation therapy in oligometastatic prostate cancer: An ESTRO-ACROP Delphi consensusThomas Zilli, Vérane Achard, Alan Dal Pra, et al.
Reports of Practical Oncology and Radiotherapy : Journal of Greatpoland Cancer Center in Poznan and Polish Society of Radiation Oncology|June 2, 2020
High-dose neoadjuvant chemoradiotherapy versus chemotherapy alone followed by surgery in potentially-resectable stage IIIA-N2 NSCLC. A multi-institutional retrospective study by the Oncologic Group for the Study of Lung Cancer (Spanish Radiation Oncology Society)Sara Montemuiño, Núria Rodriguez de Dios, Margarita Martín, et al.
European Urology Oncology|January 21, 2026
Health-related Quality of Life Outcomes of Salvage Metastasis-directed Treatment Versus Elective Nodal Treatment for Oligorecurrent Nodal Prostate Cancer: A Secondary Analysis of the Phase 2, Open-label PEACE V-STORM Randomized TrialThomas Zilli, Shankar Siva, Sigmund Brabrand, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|August 11, 2021
Randomized Phase III Trial of Prophylactic Cranial Irradiation With or Without Hippocampal Avoidance for Small-Cell Lung Cancer (PREMER): A GICOR-GOECP-SEOR StudyNúria Rodríguez de Dios, Felipe Couñago, Mauricio Murcia-Mejía, et al.
Radiotherapy and Oncology : Journal of the European Society for Therapeutic Radiology and Oncology|April 27, 2022
Oligorecurrent nodal prostate cancer: Radiotherapy quality assurance of the randomized PEACE V-STORM phase II trialVérane Achard, Maud Jaccard, Frederik Vanhoutte, et al.
The Lancet. Oncology|May 8, 2025
Salvage metastasis-directed therapy versus elective nodal radiotherapy for oligorecurrent nodal prostate cancer metastases (PEACE V-STORM): a phase 2, open-label, randomised controlled trialPiet Ost, Shankar Siva, Sigmund Brabrand, et al.
European Urology Focus|January 2, 2021
The Multicenter, Randomized, Phase 2 PEACE V-STORM Trial: Defining the Best Salvage Treatment for Oligorecurrent Nodal Prostate Cancer MetastasesThomas Zilli, Piet Dirix, Reino Heikkilä, et al.
Biomedicines|October 29, 2025
First Spanish Experience with Stereotactic MR-Guided Adaptive Radiotherapy (SMART) in Borderline Resectable and Locally Advanced Pancreatic Cancer: A Prospective StudyDaniela Gonsalves, Abrahams Ocanto, Eduardo Meilan, et al.
European Urology Oncology|October 11, 2023
PEACE V-Salvage Treatment of OligoRecurrent nodal prostate cancer Metastases (STORM): Acute Toxicity of a Randomized Phase 2 TrialPiet Ost, Shankar Siva, Sigmund Brabrand, et al.
Pageof 15